BRAF and central nervous system cancer: To assess the in vivo effects of combined BRAFi with SHP2i, we utilized heterotopic (flank) xenografts from two BRAF V600E mutant glioma cell-line models (Figure 6A, B) and one patient-derived xenograft (PDX, Figure 6C).